Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Lucid Diagnostics (LUCD) EBIAT (2021 - 2026)

Lucid Diagnostics filings provide 5 years of EBIAT readings, the most recent being -$16.3 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 40.94% to -$16.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$58.0 million, a 27.41% decrease, with the full-year FY2025 number at -$58.0 million, down 27.41% from a year prior.
  • EBIAT hit -$16.3 million in Q4 2025 for Lucid Diagnostics, down from -$10.4 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$3.7 million in Q1 2021 to a low of -$26.9 million in Q1 2025.
  • Median EBIAT over the past 5 years was -$11.5 million (2023), compared with a mean of -$12.0 million.
  • Biggest five-year swings in EBIAT: plummeted 235.89% in 2022 and later soared 59.66% in 2025.
  • Lucid Diagnostics' EBIAT stood at -$11.3 million in 2021, then tumbled by 32.04% to -$14.9 million in 2022, then increased by 27.45% to -$10.8 million in 2023, then dropped by 6.57% to -$11.5 million in 2024, then plummeted by 40.94% to -$16.3 million in 2025.
  • The last three reported values for EBIAT were -$16.3 million (Q4 2025), -$10.4 million (Q3 2025), and -$4.4 million (Q2 2025) per Business Quant data.